Bladder Cancer

Papers
(The TQCC of Bladder Cancer is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
BCG therapy for bladder cancer: Exploring patient experiences and concerns through artificial intelligence-based social media analysis9
Factors Influencing Patient Decision-Making in the Treatment of Muscle-Invasive Bladder Cancer7
Comorbidity Scores and Machine Learning Methods Can Improve Risk Assessment in Radical Cystectomy for Bladder Cancer7
Outcomes of Patients with Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer as Defined by the U.S. Food and Drug Administration6
Implementing a New Standard of Care6
North American study and meta-analysis evaluating performance of Bladder EpiCheck®, a FDA cleared test, in non-muscle invasive bladder cancer recurrence5
Cost of Care in Open Cystectomy Patients Across Time and Space: Does it matter?5
Patterns of Smoking Cessation Strategies and Perception of E-cigarette Harm Among Bladder Cancer Survivors5
Challenging Cases in Urothelial Cancer: Case 225
Optimizing Nutritional Status in Patients Undergoing Radical Cystectomy: A Systematic Scoping Review4
Single-cell RNA sequencing and spatial transcriptome analysis in bladder cancer: Current status and future perspectives4
Challenging Cases in Urothelial Cancer: Case 31: LG Ta Bladder Cancer4
Qualitative Analysis of Pain in Patients With Locally Advanced or Metastatic Urothelial Carcinoma4
Adjuvant Chemotherapy Plus Radiotherapy versus Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy4
A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E4
Quality of Life following Chemoradiotherapy for Localized Muscle Invasive Bladder Carcinoma: A Systematic Review4
Editorial Concerning “The Association Between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study”3
Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer3
Lung Metastases Versus Second Primary Lung Cancers in Patients with Primary Urothelial Carcinoma of the Bladder: A National Population-Based Assessment3
Challenging Cases in Urothelial Cancer: Case 30: Rare Complication of BCG3
Impact of Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Population Based Analysis3
The Role of Local Agents for the Treatment of Localized Upper Tract Urothelial Carcinoma: A Review of the Current Evidence3
What is a Bladder Cancer Molecular Subtype?3
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer3
Is There A Benefit of Restaging Transurethral Resection of Bladder Tumor Prior to Radical Cystectomy With or Without Neoadjuvant Chemotherapy?3
Systematic Review and Meta-Analysis of Cisplatin Based Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer2
Clinical Trials Corner Issue 7(3)2
An Association Study of Germline Variants in Bladder Cancer-Related Genes with the Prognosis of Non-Muscle Invasive Bladder Cancer2
Challenging Cases in Urothelial Cancer: Case 242
Loss of Cxcr2 in Myeloid Cells Promotes Tumour Progression and T Cell Infiltration in Invasive Bladder Cancer2
Sensitivity and Specificity in Urine Bladder Cancer Markers – Is it that Simple?2
Non-Muscle Invasive Bladder Cancer: Many More Patients Die With It Than Of It2
Single Instillation of Hypertonic Saline Immediately Following Transurethral Resection of Bladder Tumor for Recurrence Prevention –A Phase I Study2
Clinical Trials Corner Issue 9(4)2
Impact of Adjuvant Gemcitabine Containing Chemotherapy Following Radical Nephroureterectomy for Patients with Upper Tract Urothelial Carcinoma: Results from a Propensity-Score Matched Cohort Study2
The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward1
A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Re1
Achieving health equity in bladder cancer care: Addressing disparities through collaborative research and evidence-based strategies1
A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer1
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer1
The Impact of Dose Reduction of Bacillus Calmette–Guerin on Oncological Outcomes and Toxicity in Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis1
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification Models1
MHC I Expression Predicts Response to Checkpoint Inhibitors in Metastatic Urothelial Carcinoma but Lacks Prognostic Value in Localized Disease1
Repeat TURBT in large volume high-grade non-invasive bladder cancer1
Longitudinal Analysis of Bladder Cancer-Specific Mortality Trends in the United States1
Practice patterns and outcomes of conventional versus split-dose cisplatin in neoadjuvant ddMVAC in bladder cancer1
Open vs Robotic Surgery1
Clinical Trials Corner Issue 8(1)1
Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: Evaluating treatment outcomes1
No Association Between BCG Instillations and COVID-19 Incidence in a Dutch Non-Muscle Invasive Bladder Cancer Cohort1
Urethral Melanoma – Clinical, Pathological and Molecular Characteristics1
NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors1
A Procedural Checklist for Transurethral Resection of Bladder Tumors (TURBT) Enhances Operative Dictation and Assesses Surgeon Accuracy of Tumor Characteristic Predictions1
0.12141799926758